SEC Tracker
Get the app
NEUP · XBRL financial data

Neuphoria Therapeutics financial statements, every quarter

The same tables from 11 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NEUP's year ends in late June)

In millions of dollarsJun 30, 2022Jun 30, 2023Jun 30, 2024Sep 30, 2024†Feb 12, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue——————year only———year only
Revenue from contracts with customers—————15(0)*————
Research and development—year only3*2—24*41——
General and administrative—year only2*2—12*2222*
Total operating expenses—year only5*4—36*6417*
Operating income (loss)—year only(5)*(4)—12(6)*(6)(4)(1)(6)*
Interest income—year only0*0—00*0000*
Income tax expense (benefit)—year only(0)*(0)—(0)(0)*(0)(0)(0)(0)*
Net income (loss)—year only(3)*(1)—11(9)*(10)2(1)(5)*
Earnings per share, basic USD per share———0.00—6.55—(4.41)0.41(0.09)—
Earnings per share, diluted USD per share———0.00—6.55—(4.41)(0.77)(0.09)—
Weighted average shares, basic millions of shares———2,808—2—2555*
Weighted average shares, diluted millions of shares———2,808—2—2555*
Revenue millions of AUDyear onlyyear only—————————
Research and development millions of AUDyear onlyyear only—————————
Profit (loss) millions of AUDyear onlyyear only—————————
  • † Share count changed about 1/2000 in the period ending 2025-02-12, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (NEUP's year ends in late June)

In millions of dollarsJun 30, 2022Jun 30, 2023Jun 30, 2024Sep 30, 2024†Feb 12, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2312138—171414221920
Accounts receivable—000—000121
Total current assets—13138—171514232221
Property and equipment, net—000—000———
Right-of-use asset—000—000———
Goodwill9999—899993
Total assets—292823—312927373529
Accounts payable—121—111110
Total current liabilities—343—245321
Lease liability, non-current—000—0—————
Total liabilities—7106—51015754
Accumulated deficit—(162)(178)(179)—(169)(178)(188)(186)(187)(192)
Total stockholders' equity39221717—261913302925
Total liabilities and equity—292823—312927373529
Common shares outstanding (cover page) millions of shares1,3531,4873,1183,5152225555
Cash and cash equivalents millions of AUD3418—————————
Total current assets millions of AUD4220—————————
Total assets millions of AUD6543—————————
Total current liabilities millions of AUD34—————————
Total liabilities millions of AUD810—————————
Total equity millions of AUD5733—————————
  • † Share count changed about 1/2000 in the period ending 2025-02-12, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (NEUP's year ends in late June)

In millions of dollarsJun 30, 2022Jun 30, 2023Jun 30, 2024Sep 30, 2024†Feb 12, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)—year only(3)*(1)—11(9)*(10)2(1)(5)*
Stock-based compensation—year only0*0—0*0*00*0*0*
Net cash from operating activities—year only(3)*(4)—11*(4)*(4)(6)*(3)*1*
Proceeds from issuing common stock——2*0—1*1*315*0*0*
Net cash from financing activities—year only7*(0)—1*1*315*0*0*
Net change in cash——4*(5)—13*(3)*(1)9*(3)*0*
Net cash from operating activities millions of AUDyear onlyyear only—————————
Net cash from investing activities millions of AUDyear onlyyear only—————————
Net cash from financing activities millions of AUDyear onlyyear only—————————
  • † Share count changed about 1/2000 in the period ending 2025-02-12, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
  • A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Neuphoria Therapeutics20year only1.2*5.4M— 10-KJun 30, 2026
CV Sciences0.330*225.8M— 10-QJun 30, 2026
Minerva Neurosciences25not reported(13)*47.7M5.6 quarters 10-QJun 30, 2026
Sunshine Biopharma149.3(0.9)*3.9M15.0 quarters 10-QJun 30, 2026
Zeo ScientifiX2.3not reportednot reported7.8M— 10-KTJun 30, 2026
Bolt Biotherapeutics130(6.5)*1.9M2.7 quarters 10-QJun 30, 2026
Intensity Therapeutics9.5not reported(2.3)*3.3M4.1 quarters 10-QJun 30, 2026
Protagenic Therapeutics, Inc.\new0.6not reported(0.9)1.8M0.6 quarters 10-QJun 30, 2026
Biomerica2.71.3(0.8)4.6M3.4 quarters 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.